AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
19 Gennaio 2021 - 10:41PM
Business Wire
The Trianni Mouse®, AbCellera’s technology for
generating large databases of human antibodies for drug discovery
programs, is granted United States patent
AbCellera (Nasdaq: ABCL), a technology company with a
centralized operating system for next-generation antibody
discovery, today announced it has expanded its intellectual
property (IP) portfolio to include its Trianni Mouse®
technology. AbCellera uses the transgenic animal technology
to generate fully human monoclonal antibodies for its drug
discovery programs with biotech and pharma partners. The United
States Patent and Trademark Office (USPTO) issued patent no.
10,881,084 titled “Transgenic Animals and Methods of Use” to
Trianni, Inc. (Trianni), an AbCellera Company.
“This patent is an important addition to our IP portfolio,
providing protection to our proprietary technology in the U.S.,”
said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. “By
generating fully human antibodies in the first step of the
discovery process, we’re able to increase the speed and efficiency
of our partners’ programs to develop therapeutic antibodies.”
Trianni’s genetic engineering technology, which AbCellera
acquired in November 2020, is an advanced transgenic platform for
developing mice that produce human antibodies. The flagship Trianni
Mouse® platform was designed to maximize immune responses, increase
antibody diversity, and preserve natural maturation of fully human
antibodies. It is also a core platform for quickly developing
increasingly powerful transgenic mouse technologies for use in
partner programs.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
About Trianni, Inc.
Trianni, an AbCellera company, specializes in antibody discovery
technology using transgenic mice. Trianni’s lead technology, the
Trianni Mouse®, is a next-generation platform enabling efficient
generation of diverse, fully human monoclonal antibodies. The
Trianni transgenic platform leverages a novel approach to design
made possible by advances in DNA synthesis and genomic engineering
technology. Additional information about Trianni is available at
www.trianni.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119006096/en/
Inquiries Media: Jessica Yingling, Ph.D.,
media@abcellera.com, +1(236)521-6774 Business Development:
Kevin Heyries, Ph.D., bd@abcellera.com, +1(604)559-9005 Legal
Affairs: Tryn Stimart, J.D., legal@abcellera.com, +1(604)
559-9005 Investor Relations: Melanie Solomon,
ir@abcellera.com, +1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024